Biogen Pharmachem Industries Limited reported a net profit of ₹85.95 lakh for the fiscal year ended March 31, 2026 (FY26), reversing a loss of ₹29.27 lakh in the previous year. The company has scheduled its 31st Annual General Meeting for Tuesday, September 29, 2026.

The entity, formerly known as Sun Techno Overseas Limited, generated total revenue of ₹255.80 lakh, derived entirely from other income as it had no operational revenue from its core business activities during the period.

Financial Performance

Biogen Pharmachem's financial results for FY26 highlight a shift to profitability driven by investment returns rather than operational turnover.

Other income surged to ₹255.80 lakh from ₹119.77 lakh in FY25. This increase was primarily driven by interest income of ₹193.51 lakh and capital gains of ₹59.89 lakh. The company recorded total expenses of ₹160.13 lakh, including employee benefit expenses of ₹28.28 lakh and other expenses of ₹131.85 lakh.

Balance Sheet and Assets

As of March 31, 2026, the company's total assets stood at ₹9,939.89 lakh, an increase from ₹9,201.77 lakh in the prior year. Non-current assets comprised the majority of the balance sheet, with investments valued at ₹3,278.23 lakh and long-term loans and advances amounting to ₹6,612.97 lakh.

Cash and cash equivalents decreased significantly to ₹32.16 lakh from ₹201.63 lakh in FY25. This reduction reflects cash outflows for investments and long-term advances, partially offset by proceeds of ₹630.00 lakh from the conversion of preferential warrants into equity shares.

Capital Structure

The issued, subscribed, and paid-up capital increased to ₹90,26.03 lakh, divided into 90,26,03,000 equity shares of ₹1 each. This rise followed the allotment of 25,00,00,000 fully convertible warrants into equity shares on a preferential basis to the non-promoter group on April 15, 2025.

Promoter holding remained at 0%. Significant shareholders holding more than 5% include Interface Financial Services Limited (9.31%), Parichay Infrastructure Limited (8.59%), and Rama Shiva Lease Finance Private Limited (8.26%).

Corporate Governance and AGM Details

The 31st AGM will be held through Video Conferencing or Other Audio Visual Means. Shareholders will vote on ordinary business items, including:

• Adoption of audited financial statements for FY26 along with Board and Auditor reports.
• Reappointment of Kelash Bunkar as a director retiring by rotation.
• Reappointment of M/s Goenka Mehta & Associates as statutory auditors until the AGM in 2031.

Remote e-voting will be available from Saturday, September 26, 2026, at 9:00 am to Monday, September 28, 2026, at 5:00 pm. The record date for voting rights is Tuesday, September 22, 2026.

What the Numbers Show

The company's profitability is entirely non-operational. With zero revenue from operations and total revenue comprising solely other income, the net profit of ₹85.95 lakh is driven by interest income and capital gains on investments. The significant drop in cash balances alongside an increase in long-term loans and investments suggests a strategic deployment of funds into financial assets rather than working capital for operational expansion.

Biogen Pharmachem Industries Limited reported a net profit of ₹22.14 lakh for the quarter ended June 30, 2026, marking a return to profitability after posting a net loss of ₹35.88 lakh in the preceding quarter. The company’s revenue from operations rose to ₹44.34 lakh in Q1FY26, up from ₹154.28 lakh in the same quarter last year, while total expenses declined significantly to ₹22.20 lakh from ₹93.70 lakh in Q4FY26. This turnaround highlights improved operational efficiency and cost management during the period.

The Board of Directors approved the unaudited standalone financial results during a meeting held on August 05, 2026, at the company’s registered office in Rajkot. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Goenka Mehta And Associates, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company’s financial performance in Q1FY26 showed distinct improvements across key metrics compared to both the immediate prior quarter and the corresponding period in the previous fiscal year.

Revenue from operations was entirely derived from other operating revenue, amounting to ₹44.34 lakh. There were no gross revenues from the sale of products reported for the quarter. Employee benefit expenses decreased sharply to ₹2.28 lakh from ₹10.31 lakh in the previous quarter, contributing to the reduction in total expenses. Other expenses also fell to ₹19.92 lakh from ₹83.39 lakh in Q4FY26.

What the Numbers Show

A notable aspect of the quarter’s performance is the divergence between revenue trends and expense management. While revenue from operations declined year-on-year from ₹154.28 lakh to ₹44.34 lakh, the company managed to turn profitable by drastically cutting costs. The absence of finance costs and depreciation expenses in the current quarter further aided the bottom line. Additionally, paid-up equity share capital increased to ₹10,530.37 lakh from ₹9,026.03 lakh in the previous quarter, indicating potential capital infusion or share issuance activity during the period. Earnings per share remained flat at ₹0.00 due to the large base of equity shares relative to the profit magnitude.